Oryzon Genomics
Develops diagnostic and therapeutic tools.
Launch date
Employees
Market cap
€120m
Enterprise valuation
€123m (Public information from Sep 2024)
Share price
€1.872 ORY.MC
Company register number A62291919
Cornellà de Llobregat Catalonia (HQ)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.0m | - | - | - | - | 2.1m | 7.9m |
| % growth | - | - | - | - | - | - | 269 % |
| EBITDA | (4.1m) | (5.1m) | (7.4m) | (5.1m) | (4.3m) | (4.3m) | 4.7m |
| % EBITDA margin | (68 %) | - | - | - | - | (201 %) | 59 % |
| Profit | (4.1m) | (4.2m) | (5.3m) | (4.2m) | (3.4m) | (3.6m) | (<1m) |
| % profit margin | (69 %) | - | - | - | - | (170 %) | (10 %) |
| EV / revenue | 17.4x | - | - | - | - | 59.2x | 15.1x |
| EV / EBITDA | -25.6x | -36.0x | -19.1x | -26.5x | -28.0x | -29.4x | 25.5x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | €5.3m | Post IPO Debt | |
| N/A | $800k | Grant | |
| N/A | €18.0m | Post IPO Equity | |
| N/A | €13.0m | Post IPO Equity | |
$1.5m | Grant | ||
| N/A | €20.0m | Post IPO Equity | |
| N/A | €20.0m | Post IPO Equity | |
* | N/A | €20.0m | Post IPO Convertible |
* | N/A | €400k | Grant |
* | €45.0m | Post IPO Convertible | |
| Total Funding | €34.6m | ||
Related Content
Recent News about Oryzon Genomics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Oryzon Genomics
Edit
ACQUISITION by Oryzon Genomics Mar 2009